CIK 0001590877
- Non-accelerated filer
- Smaller reporting company
REGENXBIO Inc.
Sign in to watch- Ticker
- RGNX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 471851754
- Phone
- +1 240-552-8181
- Business address
- 9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
- Former names
- ReGenX Biosciences, LLC
- Open-market buys, last 90 days
- $949,381
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$949,381. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-01-03 | Simpson Curran SVP, Product Development & CTO | Grant or award · Stock Option (Right to Buy) | +46,000 | 46,000 | ||
| 2019-01-03 | Danos Olivier Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +48,000 | 48,000 | ||
| 2019-01-03 | Vasista Vittal Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +57,000 | 57,000 | ||
| 2019-01-03 | Mills Kenneth T. President and CEO | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2018-12-31 | Christmas Patrick J. SVP, General Counsel | Grant or award | +337 | $35.66 | $12K | 3,006 |
| 2018-12-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion | +5,000 | $12.10 | $61K | 7,669 |
| 2018-12-18 | Christmas Patrick J. SVP, General Counsel | Sale | −2,225 | $46.79 | $104K | 5,444 |
| 2018-12-18 | Christmas Patrick J. SVP, General Counsel | Sale | −2,055 | $47.85 | $98K | 3,389 |
| 2018-12-18 | Christmas Patrick J. SVP, General Counsel | Sale | −720 | $48.97 | $35K | 2,669 |
| 2018-12-18 | Christmas Patrick J. SVP, General Counsel | Exercise or conversion · Employee Stock Option (Right to Buy) | −5,000 | 53,472 | ||
| 2018-12-17 | Vasista Vittal Chief Financial Officer | Sale | −4,100 | $45.73 | $187K | 125,683 |
| 2018-12-17 | Vasista Vittal Chief Financial Officer | Sale | −1,700 | $46.47 | $79K | 123,983 |
| 2018-12-17 | Vasista Vittal Chief Financial Officer | Sale | −1,700 | $47.74 | $81K | 122,283 |
| 2018-12-17 | Mills Kenneth T. President and CEO | Sale | −7,604 | $46.11 | $351K | 223,396 |
| 2018-12-17 | Mills Kenneth T. President and CEO | Sale | −2,988 | $46.81 | $140K | 220,408 |
| 2018-12-17 | Mills Kenneth T. President and CEO | Sale | −4,408 | $47.74 | $210K | 216,000 |
| 2018-12-03 | Yoo Stephen Chief Medical Officer | Exercise or conversion | +20,414 | $0.85 | $17K | 20,414 |
| 2018-12-03 | Yoo Stephen Chief Medical Officer | Sale | −6,854 | $59.62 | $409K | 13,560 |
| 2018-12-03 | Yoo Stephen Chief Medical Officer | Sale | −13,053 | $60.35 | $788K | 507 |
| 2018-12-03 | Yoo Stephen Chief Medical Officer | Sale | −507 | $61.20 | $31K | 0 |
Page 31 of 43 · 852 trades